Methocarbamol and Shock haemorrhagic - a phase IV clinical study of FDA data


Shock haemorrhagic is reported only by a few people who take Methocarbamol.

The phase IV clinical study analyzes which people take Methocarbamol and have Shock haemorrhagic. It is created by eHealthMe based on reports of 13,530 people who have side effects while taking Methocarbamol from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 11, 2022

13,530 people reported to have side effects when taking Methocarbamol.
Among them, 5 people (0.04%) have Shock haemorrhagic.

What is Methocarbamol?

Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 14,406 Methocarbamol users for its effectiveness, alternative drugs and more.

What is Shock haemorrhagic?

Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding) is found to be associated with 1,050 drugs and 753 conditions by eHealthMe.

Number of Methocarbamol and Shock haemorrhagic reports submitted per year:

Could Methocarbamol cause Shock haemorrhagic?

Time on Methocarbamol when people have Shock haemorrhagic *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Shock haemorrhagic when taking Methocarbamol *:

  • female: 75 %
  • male: 25 %

Age of people who have Shock haemorrhagic when taking Methocarbamol *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 75 %
  • 50-59: 0.0 %
  • 60+: 25 %

Common drugs people take besides Methocarbamol *:

  1. Xarelto: 2 people, 40.00%
  2. Movicol: 2 people, 40.00%
  3. Xeloda: 1 person, 20.00%
  4. Promethazine: 1 person, 20.00%
  5. Pantoprazole: 1 person, 20.00%
  6. Paclitaxel: 1 person, 20.00%
  7. Oxycontin: 1 person, 20.00%
  8. Neupogen: 1 person, 20.00%
  9. Docetaxel: 1 person, 20.00%
  10. Dexamethasone Acetate: 1 person, 20.00%

Common side effects people have besides Shock haemorrhagic *:

  1. Haematemesis (vomiting of blood): 2 people, 40.00%
  2. Gastric Ulcer (stomach ulcer): 2 people, 40.00%
  3. Toothaches (tooth pain): 1 person, 20.00%
  4. Pharyngitis (inflammation of the pharynx, causing a sore throat): 1 person, 20.00%
  5. Multi-Organ Failure (multisystem organ failure): 1 person, 20.00%
  6. Lower Gastrointestinal Haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding): 1 person, 20.00%
  7. Gastric Cancer (stomach cancer): 1 person, 20.00%
  8. Fall: 1 person, 20.00%
  9. Bone Marrow Failure: 1 person, 20.00%
  10. Anaemia (lack of blood): 1 person, 20.00%

Common conditions people have *:

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 40.00%
  2. Constipation: 2 people, 40.00%
  3. White Blood Cell Count Decreased: 1 person, 20.00%
  4. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 20.00%
  5. Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 20.00%
  6. Pain: 1 person, 20.00%
  7. Gastric Cancer Recurrent (repeat stomach cancer): 1 person, 20.00%
  8. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 1 person, 20.00%
  9. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 20.00%
  10. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Methocarbamol and have Shock haemorrhagic?

Check whether Shock haemorrhagic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Shock haemorrhagic and when was it recovered:

Expand to all the drugs that have ingredients of methocarbamol:

Alternative drugs to, pros and cons of Methocarbamol:

Common Methocarbamol side effects:

Browse all side effects of Methocarbamol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Shock haemorrhagic treatments and more:

COVID vaccines that are related to Shock haemorrhagic:

Common drugs associated with Shock haemorrhagic:

All the drugs that are associated with Shock haemorrhagic:

Common conditions associated with Shock haemorrhagic:

All the conditions that are associated with Shock haemorrhagic:

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Methocarbamol) and Methocarbamol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: